Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.
about
Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosisContribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosisWhole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance EscalationUnderstanding pharmacokinetics to improve tuberculosis treatment outcome.Plasma drug activity assay for treatment optimization in tuberculosis patients.Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisRedefining multidrug-resistant tuberculosis based on clinical response to combination therapy.An upstream truncation of the furA-katG operon confers high-level isoniazid resistance in a Mycobacterium tuberculosis clinical isolate with no known resistance-associated mutations.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBTherapy duration and long-term outcomes in extra-pulmonary tuberculosis.Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates.Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan.Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistanceMycobacterial shuttle vectors designed for high-level protein expression in infected macrophages.Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in BabiesMoxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through effluxSerum drug concentrations predictive of pulmonary tuberculosis outcomes.Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium.Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.Nonclinical models for antituberculosis drug development: a landscape analysis.Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant TuberculosisDo Shoot the Messenger: PASTA Kinases as Virulence Determinants and Antibiotic Targets.Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.
P2860
Q24609872-8AED0378-9A75-4D00-9113-3AE037F93E23Q28482174-17424A0C-62D0-4F40-B18A-08B749A6BBF9Q28547769-550708D2-6945-4419-BC00-65A6A3977BD8Q30411703-253E1755-53C0-40C3-829B-271E6679C9BCQ30426583-0EC8614C-3CE4-4008-8816-BA7B34DE2548Q33868685-78B07FA6-FD37-4FE3-A07E-C3E92A443B5CQ33926262-59F81E4C-8322-4C6A-809F-B42ED5733CD3Q34298988-691CB774-CF7F-400B-9214-B1F348C0B461Q34299052-8C99DA09-159B-4DD4-9268-44EA058A72C7Q34591451-B68F9079-ECDB-416F-B170-F03649FCC95EQ35104725-1AEA47E9-A36F-4FDD-B75B-9DFF35043DE8Q35167178-EC289EE3-7E5A-4953-A35D-C424558D5921Q35169089-F171666C-CC74-4B97-9A6E-5DA46E987BB1Q35242238-7360AFDC-868B-4A64-B388-D1264AE2F202Q35562635-0861475E-4162-4E7C-BDE8-166D0843B714Q35598510-6339F1D2-9C94-4EDE-9DC2-44F20F5E2988Q35806375-6C4C097A-D5E5-48AC-91F7-C8C394A750F3Q35878689-9E904526-B156-43A7-9F46-FDDEFFE681BAQ36172383-A1190B01-F02B-44AA-9A4F-220593E1E9E6Q36277210-E5B3A1F2-7648-4644-81EB-656D9494B8D8Q36540893-99DECEDD-FBC0-424A-BF08-40B3E1F23175Q36869913-C230D3EC-03CE-4881-A90D-EEA1C7BFF701Q36933441-6A773648-8A9D-4015-97E2-B99D14EDB176Q36974201-52C55845-D0B1-4D13-A5DC-F824721F8D6CQ37213037-7F8CF5D6-DA14-4B97-B401-CA511FC9A990Q37339294-10F823B8-7AB7-40CC-8CD8-C92CFDC290C6Q37385024-535680BC-7EDD-44C5-A724-58ACE4194542Q37799461-1561B21D-018F-4BAB-B516-41FF00D69004Q37869912-24277798-388E-4A66-8646-D09911B6FD58Q38056146-AF8F2AE9-6FD3-41D0-831F-1681B25488C9Q38502294-69354CD5-1120-4944-BE83-93EC5087D606Q38502298-342AF8BF-301E-40E2-946E-4E01861D46EEQ38979626-3155DA23-8019-406C-9925-7F0EF7892C4BQ39030684-780DD159-926C-473B-B927-37449AA1271AQ39451994-E1737EFB-7A8E-4223-88D7-E10CFB81B7A7Q39715580-E61A4886-7E60-4489-A00A-A09CA38BC23DQ39895097-0877D0E0-6BA1-4FA6-BAEC-634D42DEC452Q40139981-02773676-D516-4657-8DF6-7830225E855CQ40139991-C7347488-4229-4B56-A7F2-6E47F69A58F6Q40155324-83951937-6993-4362-A198-5E76FF2888B4
P2860
Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Efflux-pump-derived multiple d ...... harmacodynamics of ethambutol.
@en
Efflux-pump-derived multiple d ...... harmacodynamics of ethambutol.
@nl
type
label
Efflux-pump-derived multiple d ...... harmacodynamics of ethambutol.
@en
Efflux-pump-derived multiple d ...... harmacodynamics of ethambutol.
@nl
prefLabel
Efflux-pump-derived multiple d ...... harmacodynamics of ethambutol.
@en
Efflux-pump-derived multiple d ...... harmacodynamics of ethambutol.
@nl
P2093
P2860
P356
P1476
Efflux-pump-derived multiple d ...... harmacodynamics of ethambutol.
@en
P2093
Carleton Sherman
Claudia Meek
Richard Leff
Sandirai Musuka
P2860
P304
P356
10.1086/651377
P407
P577
2010-04-01T00:00:00Z